Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.86 USD | +0.02% | +20.81% | +46.49% |
03:20pm | HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating | MT |
05-16 | Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+46.49% | 12.05M | |
+42.52% | 54.04B | |
+43.57% | 41.96B | |
-1.26% | 41.92B | |
-7.59% | 28.35B | |
+11.71% | 26.35B | |
-22.32% | 19B | |
+7.90% | 13B | |
+28.97% | 12.28B | |
+25.59% | 12.19B |
- Stock Market
- Equities
- IKT Stock
- News Inhibikase Therapeutics, Inc.
- Transcript : Inhibikase Therapeutics, Inc., 2023 Earnings Call, Mar 28, 2024